Agenus Inc. (AGEN)
Agenus Inc. - France Expands National AAC Access for Agenus Botensilimab + Balstilimab for Ovarian Cancer and Soft-Tissue Sarcomas
Agenus Inc. - France Expands National AAC Access for Agenus Botensilimab + Balstilimab for Ovarian Cancer and Soft-Tissue Sarcomas
📊 **NEUTRAL** • Medium confidence analysis (70%) • Weak clinical signals • Minimal impact anticipated **Sentiment:** Neutral (50%) **Content type:** Clinical